Press Releases Subscribe to our News
Regulatory
Biosergen publishes interim report for first quarter 2023
ReleaseQ1-2023 Financial Report
Regulatory
Biosergen publishes interim report for fourth quarter 2022
ReleaseQ4-2022 Financial Report
Non-Regulatory
Biosergen will be participating in Investerarträff arranged by Financial Stockholm, March 29
Non-Regulatory
Biosergen will be participating at Mangold Insight Investor Day, March 22
Non-Regulatory
Carlsquare has initiated its coverage of Biosergen
Non-Regulatory
Positive topline data from phase 1 study of BSG005 shows it is safe and well tolerated. It gives hope for a change in the treatment paradigm of patients with invasive fungal infections.
ReleaseNon-Regulatory
Biosergen completes the first Multiple Ascending Dose (MAD) cohort of BSG005 phase I trial
ReleaseNon-Regulatory
The first volunteer has been dosed in the MAD part of the Phase I trial of BSG005
ReleaseRegulatory
Biosergen publishes interim report for third quarter 2022
ReleaseQ3-2022 Financial Report
Non-Regulatory
Biosergen allocates shares to an underwriter in connection with the completed rights issue
ReleaseNon-Regulatory
The subscription period in Biosergen’s rights issue starts today
Non-Regulatory
Biosergen AB: Biosergen publishes prospectus due to rights issue of units
ReleaseEU-tillväxtprospekt - Biosergen
Regulatory
Biosergen moves into the MAD (Multiple Ascending Dose) part of its phase I study after 4 cohorts tested in the SAD (Single Ascending Dose) part of the study.
ReleaseRegulatory
Biosergen AB: Biosergen’s Board of Directors decides on a rights issue of units of approximately SEK 60.2 million
ReleaseRegulatory
Biosergen publishes interim report for second quarter 2022
ReleaseQ2-2022 Financial Report
Non-Regulatory
3P Biopharmaceuticals and Biosergen complete together the manufacture of biomass for the Mucormycosis “Black Fungus” clinical phase II trial.
ReleaseRegulatory
Announcement from the annual general meeting held on June 28, 2022 in Biosergen AB
ReleaseRegulatory
Biosergen publishes interim report for first quarter 2022
Release2022-Q1 Financial Report
Non-Regulatory
Biosergen is preparing a Phase II study of BSG005 against Mucormycosis, the Black Fungus.
ReleaseNon-Regulatory
The first subjects dosed successfully with no adverse events in the phase I trial of BSG005
ReleaseRegulatory
Biosergen publishes interim report for fourth quarter 2021
Biosergen Q4 financial report press releaseQ4-2021 Financial Report
Regulatory
Biosergen publishes interim report for the third quarter 2021
Q3-2021 Financial ReportBiosergen Q3 financial report press release
Regulatory
Biosergen publishes interim report for the second quarter 2021
Q2-2021 Financial ReportBiosergen Q2 report press release
Non-Regulatory
Biosergen’s application to start human clinical trials with BSG005 is approved
ReleaseRegulatory
Biosergen’s groundbreaking antifugal drug BSG005 is granted Orphan Drug status in the United States
ReleaseNon-Regulatory
BIOSERGEN HAS BEEN APPROVED FOR LISTING ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM.
Biosergen listing approvalNon-Regulatory
The outbreak of mucormycosis (the so-called “Black Fungus”) in India is a prime example of the great need for a safer antifungal drug with true fungicidal activity
ReleaseNon-Regulatory
BIOSERGEN INTENDS TO LIST ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM
BIOSERGEN INTENDS TO LIST ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM (PDF)Non-Regulatory
